top of page
Header Background.jpg


Faknostics Logo.png



Chief Executive Office, Co-founder

Ms Thompson is the co-founder of FAKnostics, LLC, and currently serves as CEO.  She had 20 years of experience in corporate, foundation, and individual fundraising for non-profit institutions before transitioning to life science startup business development. For the last 9 years, she has been employed by pharmaceutical startup companies, providing fundraising, business development, and operational support. 

Jennifer Thompson

Chief Scientific Officer

Dr. Marlowe leads the research & development efforts at FAKnostics, LLC. He is also a Research Assistant Professor at the University of Arizona College of Medicine–Phoenix and University of Arizona College of Pharmacy. Furthermore, Dr. Marlowe is the Director of UA Molecular Discovery Core Facility, which specializes in high-throughput screening, SPR, medicinal chemistry, and assay design. Dr. Marlowe is the inventor of the FAK peptide technology (U.S. Patent Application No. 65/894,726) and will direct the research and development of the FAK inhibitor. He has an extensive background in drug discovery and pharmacology, with major expertise in structure-based drug design, computational drug discovery, and a wide-variety of biophysical/biochemical assays. He received his PhD from the Roswell Park Cancer Institute in Molecular Pharmacology and Cancer Therapeutics, and his BS from the University at Buffalo in Pharmacology and Toxicology.

Timothy Marlowe
bottom of page